Primary Cardiovascular Risk Prevention With Aspirin in Chronic Kidney Disease Patients

Inclusion Criteria: * sign informed consent * males 45-79 years or females 55-79 years. -Stage 3 or 4 CKD (estimated GFR by MDRD abbreviated, between 15 and 60 ml / min/1.73 m2) - Exclusion Criteria: * a previous cardiovascular event: cardiac arrhythmias, cardiac arrest, angina or acute myocardial infarction, stroke, carotid stenosis of more than 50%, peripheral vascular arteriopathy documented * hospitalization for any cause in the last three months prior to inclusion in the study allergy of acetyl-salicylic acid * coagulopathy from any cause * thrombocytopenia \<150,000 platelets * liver disease from any cause * Infection by hepatitis B virus, hepatitis C or HIV * immunosuppressive treatment within 12 weeks before inclusion in the study * Major bleeding events including gastrointestinal bleeding and brain hemorrhage. * hemoglobinopathies (eg sickle cell disease or thalassemia of any kind) * active malignancy (except non-melanoma skin cancer). May be included in the study patients with malignant neoplasia who have remained disease-free for at least the previous 5 years. * uncontrolled inflammatory disease or symptomatic (eg rheumatoid arthritis, lupus, Chrom disease or bowel inflammatory disease) * hemolysis * treatment with oral anticoagulation and / or antiplatelet therapy prior. * poorly controlled hypertension (\> 160/90 mm Hg) -pregnancy or breast- * women of childbearing potential not using effective contraception.